Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.

Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C.

J Neurol. 2012 May;259(5):898-905. doi: 10.1007/s00415-011-6275-7. Epub 2011 Oct 19.

PMID:
22008873
2.

Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.

Cree BA, Stuart WH, Tornatore CS, Jeffery DR, Pace AL, Cha CH.

Arch Neurol. 2011 Apr;68(4):464-8. doi: 10.1001/archneurol.2011.45.

PMID:
21482925
3.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16.

PMID:
20236661
4.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

J Neurol. 2009 Mar;256(3):405-15. doi: 10.1007/s00415-009-0093-1. Epub 2009 Mar 18. Erratum in: J Neurol. 2009 Jun;256(6):1035-7.

PMID:
19308305
5.

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

Neurology. 2007 Oct 2;69(14):1391-403. Epub 2007 Aug 29.

PMID:
17761550
6.

Health-related quality of life in multiple sclerosis: effects of natalizumab.

Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

Ann Neurol. 2007 Oct;62(4):335-46.

PMID:
17696126
7.

Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.

Stuart WH.

Curr Med Res Opin. 2007 Jun;23(6):1199-208. Epub 2007 Apr 23. Review.

PMID:
17559719
8.

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.

Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA.

Neurology. 2007 Apr 17;68(16):1299-304.

PMID:
17438220
9.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

N Engl J Med. 2006 Mar 2;354(9):911-23.

10.

Concomitant therapy for multiple sclerosis.

Stuart WH, Vermersch P.

Neurology. 2004 Dec 14;63(11 Suppl 5):S28-34. Review.

PMID:
15596733
11.

Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis.

Stuart WH, Cohan S, Richert JR, Achiron A.

Neurology. 2004 Dec 14;63(11 Suppl 5):S19-27. Review.

PMID:
15596732
12.

Stepped-care approach to treating MS: a managed care treatment algorithm.

Rich SR, Coleman IC, Cook R, Hum DS, Johnson B, Maves T, Mazanec WJ, Miller JR, Proveaux WJ, Rossman HS, Stuart WH.

J Manag Care Pharm. 2004 Jun;10(3 Suppl B):S26-32. Review.

13.

Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management.

Stuart WH.

J Manag Care Pharm. 2004 Jun;10(3 Suppl B):S19-25. Review.

PMID:
15253686
14.

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite.

Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, Pfohl DC, Mills M, Bowen J, Ford C, Heidenreich FR, Jacobs DA, Markowitz CE, Stuart WH, Ying GS, Galetta SL, Maguire MG, Cutter GR.

Neurology. 2003 Nov 25;61(10):1367-73.

PMID:
14638957
15.

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Neurology. 2003 Sep 9;61(5):602-11.

PMID:
12963748
16.

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

Neurology. 2002 Jan 22;58(2):169-78. No abstract available. Erratum in: Neurology 2002 Aug13;59(3):480.

PMID:
11805241
17.

A novel population of B7-1+ T cells producing intracellular IL-4 is decreased in patients with multiple sclerosis.

Kipp B, Bar-Or A, Gausling R, Oliveira EM, Fruhan SA, Stuart WH, Hafler DA.

Eur J Immunol. 2000 Jul;30(7):2092-100.

18.

Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis.

Munschauer FE 3rd, Stuart WH.

Clin Ther. 1997 Sep-Oct;19(5):868-82. Review.

PMID:
9385476
19.

Guidelines on the vegetative state: commentary on the American Academy of Neurology statement.

Munsat TL, Stuart WH, Cranford RE.

Neurology. 1989 Jan;39(1):123-4. No abstract available.

PMID:
2909899
20.

Geriatric neurology for the otolaryngologist.

Stuart WH.

Otolaryngol Clin North Am. 1982 May;15(2):329-51. No abstract available.

PMID:
7088565
21.

An outbreak in 1965 of severe respiratory illness caused by the Legionnaires' disease bacterium.

Thacker SB, Bennett JV, Tsai TF, Fraser DW, McDade JE, Shepard CC, Williams KH Jr, Stuart WH, Dull HB, Eickhoff TC.

J Infect Dis. 1978 Oct;138(4):512-9.

PMID:
361897
22.

Indications for cerebral angiography in cerebrovascular disease. A neurologist's approach.

Stuart WH.

J Med Assoc Ga. 1972 Jun;61(6):257. No abstract available.

PMID:
5069370
23.

L-dopa and parkinsonism.

Stuart WH.

J Med Assoc Ga. 1970 Aug;59(8):331-2. No abstract available.

PMID:
5451035
24.

Hereditary cerebello-olivary degeneration of late onset.

Hoffman PM, Stuart WH, Earle KM, Brody JA.

Neurology. 1970 Apr;20(4):400. No abstract available.

PMID:
5535038
25.

Evaluation of monovalent influenza vaccine in a retirement community during the epidemic of 1965-66.

Stuart WH, Dull HB, Newton LH, McQueen JL, Schiff ER.

JAMA. 1969 Jul 14;209(2):232-8. No abstract available.

PMID:
5819227
26.

Familial myoclonus.

Stuart WH, Schwartz JF, Mayer WB, Karp HE.

Neurology. 1968 Mar;18(3):302. No abstract available.

PMID:
5690405
27.

Performance characteristics of the right heart bypass preparation.

GRODINS FS, STUART WH, VEENSTRA RL.

Am J Physiol. 1960 Mar;198:552-60. No abstract available.

PMID:
13829486

Supplemental Content

Loading ...
Support Center